CPRIT awards $26 million in new recruitment grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Prevention and Research Institute of Texas awarded nine new academic research grants totaling $26 million to recruit cancer researchers to Texas.

“Applications to recruit distinguished cancer researchers from across the country and abroad continue to increase even during the pandemic because Texas is now a magnet for world-class cancer research,” CPRIT CEO Wayne Roberts, said in a statement.

The nine potential recruits will join 218 CPRIT Scholars working at 21 institutions across Texas. Two Established Investigator awards will allow MD Anderson Cancer Center to bring researchers from two cancer research institutions in the United Kingdom. CPRIT’s Oversight Committee also approved seven First-Time, Tenure-Track Faculty Member recruitment awards for promising young researchers from California, Massachusetts and Switzerland.

In addition to MD Anderson, the institutions receiving grants today include Baylor College of Medicine, The University of Texas Health Science Center at San Antonio, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center.

The grants awarded and their recipients follow:

Recruitment of Established Investigators Awards*—Two grants totaling $12 million

  • Bissan Al-Lazikani, Recruitment to MD Anderson Cancer Center from the Institute of Cancer Research – $6 million

  • Peter Van Loo, Recruitment to MD Anderson Cancer Center from The Francis Crick Institute – $6 million

Recruitment of First-Time, Tenure-Track Faculty Members Awards* – Seven grants totaling $14 million

  • Furqan Fazal, Recruitment to Baylor College of Medicine from Stanford University School of Medicine – $2 million

  • Guy Nir, Recruitment to The University of Texas Medical Branch at Galveston from Harvard Medical School – $2 million

  • Jihan Osborne, Recruitment to The University of Texas Southwestern Medical Center from Boston Children’s Hospital, Harvard Medical School – $2 million

  • Xiaoli Sun, Recruitment to The University of Texas Health Science Center at San Antonio from University of California San Diego – $2 million

  • Jeanine Van Nostrand, Recruitment to Baylor College of Medicine from The Salk Institute for Biological Studies – $2 million

  • Pavan Bachireddy, Recruitment to The University of Texas MD Anderson Cancer Center from the Dana Farber Cancer Institute – $2 million

  • Mauro Di Pilato, Recruitment to The University of Texas MD Anderson Cancer Center from the Institute for Research in Biomedicine – $2 million

CPRIT awards three types of recruitment grants: Established Investigators for senior research faculty with distinguished professional careers and established cancer research programs; Rising Stars for early-stage investigators who have demonstrated promising continued and enhanced contributions to the field; and First-Time, Tenure-Track Faculty awards for emerging investigators pursuing their first faculty appointment, and who are expected to make outstanding contributions in cancer research. Recruits receive the “CPRIT Scholar” designation.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login